Author

Paul W. Hogg

Institution: Adc Therapeutics (Switzerland)

Observed institution: Adc Therapeutics (Switzerland)

ORCID: 0009-0009-4255-3870

Observed ORCID: 0009-0009-4255-3870

OpenAlex ID: A5036283440

Abstract 744: ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors

2018 · Francesca Zammarchi, Karin Havenith, et al. · Cancer Research · 10

Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors

2018 · Francesca Zammarchi, Karin Havenith, et al. · Cancer Research · 6

Abstract 5085: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing NaPi2b

2024 · Elizabeth Horsley, Asma Jabeen, et al. · Cancer Research · 4

Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6

2024 · Nicola Tsang, Nicolas Veillard, et al. · Cancer Research · 3

Abstract 1580: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers

2025 · Danilo Cucchi, Elizabeth Horsley, et al. · Cancer Research · 2

Abstract 6736: Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer

2025 · Ben Leatherdale, Beccie Martin, et al. · Cancer Research · 2

A molecular glue degrader-antibody conjugate for HER2-targeted cyclin K degradation

2026 · Sofia Srdanovic, Alina Chrzastek, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2026 · Asma Jabeen, Ben Leatherdale, et al. · Molecular Cancer Therapeutics

Works count: 8

Citation count: 27

H-index: 3

I10-index: 1